Grifols receives $21M to develop early Parkinson's detection biomarkers through a decade-long plasma study.

Grifols, a healthcare company, has received a $21 million grant from the Michael J. Fox Foundation to develop early detection biomarkers for Parkinson's disease (PD). The project, called Chronos-PD, will analyze plasma samples over a decade to identify biological signals that could predict PD before symptoms appear. This initiative, led by Grifols' subsidiary Alkahest, aims to revolutionize PD management by facilitating earlier diagnosis and more effective treatments.

2 months ago
6 Articles